Health Catalyst secures $100M to expand machine learning solutions

Utah-based healthcare big data company Health Catalyst announced it has closed $100 million in Series F equity and debt funding. Financing will support the expansion of Health Catalyst’s technology and services offering for healthcare information. 

Health Catalyst’s key product, the Data Operating System, offers predictive analytics designed for population health and value-based care, with a set of machine learning solutions. The company has raised nearly $400 million to date, according to Crunchbase

“As more healthcare organizations are coming to understand, the future of healthcare will rely on the broad and more effective use of their vast stores of data,” Health Catalyst CEO Dan Burton, said in a prepared statement.

The funding round was led by healthcare investment firm OrbiMed. Other investors include Sequoia Capital, Norwest Venture Partners, Sands Capital Ventures, UPMC Enterprises and Kaiser Permanente Ventures.

“This additional capital will enable us to continue developing the technology and expertise necessary to offer health systems a path to systematically use data to analyze their performance, and then work to make measurable improvement in clinical, financial and operational areas," Burton said. "It will also help to support our expansion, already underway, into the life sciences and international markets.”

""

As a senior news writer for TriMed, Subrata covers cardiology, clinical innovation and healthcare business. She has a master’s degree in communication management and 12 years of experience in journalism and public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.